Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells.

Chen Y, Tsai YH, Tseng BJ, Pan HY, Tseng SH.

J Pediatr Surg. 2016 Nov;51(11):1818-1825. doi: 10.1016/j.jpedsurg.2016.07.003. Epub 2016 Jul 22.

PMID:
27492819
2.

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.

3.

Differential Expression of MicroRNA-19b Promotes Proliferation of Cancer Stem Cells by Regulating the TSC1/mTOR Signaling Pathway in Multiple Myeloma.

Wang N, Liang X, Yu W, Zhou S, Fang M.

Cell Physiol Biochem. 2018;50(5):1804-1814. doi: 10.1159/000494821. Epub 2018 Nov 5.

4.

MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR).

Wu D, Huang HJ, He CN, Wang KY.

Int J Gynecol Cancer. 2013 Sep;23(7):1191-7. doi: 10.1097/IGC.0b013e31829ea779.

PMID:
23851675
5.

Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.

Xu DQ, Toyoda H, Qi L, Morimoto M, Hanaki R, Iwamoto S, Komada Y, Hirayama M.

Biochem Biophys Res Commun. 2018 May 15;499(3):425-432. doi: 10.1016/j.bbrc.2018.03.143. Epub 2018 Mar 30.

PMID:
29571732
6.

Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.

Huang S, Yang ZJ, Yu C, Sinicrope FA.

J Biol Chem. 2011 Nov 18;286(46):40002-12. doi: 10.1074/jbc.M111.297432. Epub 2011 Sep 23.

7.

miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer.

Wei F, Liu Y, Guo Y, Xiang A, Wang G, Xue X, Lu Z.

Mol Cancer. 2013 Jul 25;12:81. doi: 10.1186/1476-4598-12-81.

8.

Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.

Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S.

J Biol Chem. 2013 Dec 6;288(49):35287-96. doi: 10.1074/jbc.M113.495986. Epub 2013 Oct 16.

9.

HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.

Chen SM, Guo CL, Shi JJ, Xu YC, Chen Y, Shen YY, Su Y, Ding J, Meng LH.

Int J Cancer. 2014 Nov 15;135(10):2462-74. doi: 10.1002/ijc.28880. Epub 2014 Apr 17.

10.

AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression.

Chen Y, Lee CH, Tseng BY, Tsai YH, Tsai HW, Yao CL, Tseng SH.

Anticancer Res. 2018 Mar;38(3):1445-1454.

PMID:
29491070
11.

The GAS5/miR-222 Axis Regulates Proliferation of Gastric Cancer Cells Through the PTEN/Akt/mTOR Pathway.

Li Y, Gu J, Lu H.

Dig Dis Sci. 2017 Dec;62(12):3426-3437. doi: 10.1007/s10620-017-4831-4. Epub 2017 Nov 2.

PMID:
29098549
12.

The MicroRNA-17-92 cluster enhances axonal outgrowth in embryonic cortical neurons.

Zhang Y, Ueno Y, Liu XS, Buller B, Wang X, Chopp M, Zhang ZG.

J Neurosci. 2013 Apr 17;33(16):6885-94. doi: 10.1523/JNEUROSCI.5180-12.2013.

13.

Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway.

Liu GL, Yang HJ, Liu B, Liu T.

J Cell Biochem. 2017 Oct;118(10):3424-3434. doi: 10.1002/jcb.25999. Epub 2017 May 30.

PMID:
28322459
14.

Kaempferol inhibits proliferation, migration, and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21.

Zhu G, Liu X, Li H, Yan Y, Hong X, Lin Z.

Int J Immunopathol Pharmacol. 2018 Mar-Dec;32:2058738418814341. doi: 10.1177/2058738418814341.

15.

MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.

Hu Y, Zhu Q, Tang L.

PLoS One. 2014 Mar 17;9(3):e92099. doi: 10.1371/journal.pone.0092099. eCollection 2014.

16.

MiR-181b regulates autophagy in a model of Parkinson's disease by targeting the PTEN/Akt/mTOR signaling pathway.

Li W, Jiang Y, Wang Y, Yang S, Bi X, Pan X, Ma A, Li W.

Neurosci Lett. 2018 May 14;675:83-88. doi: 10.1016/j.neulet.2018.03.041. Epub 2018 Mar 30.

PMID:
29608948
17.

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.

Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME.

Mol Cancer. 2014 Oct 6;13:229. doi: 10.1186/1476-4598-13-229.

18.

mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S, Wiltrout RH.

Cancer Res. 2011 Jun 15;71(12):4074-84. doi: 10.1158/0008-5472.CAN-10-3968. Epub 2011 May 3.

19.

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.

Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N.

Mol Cancer Ther. 2014 Nov;13(11):2489-500. doi: 10.1158/1535-7163.MCT-14-0147. Epub 2014 Aug 29.

20.

MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.

Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X, Zheng L, Xue Z, Xia W, Zhang B, Ding T, Cao Y, Tian Z, Shi Q, He X.

BMC Cancer. 2012 Nov 23;12:546. doi: 10.1186/1471-2407-12-546.

Supplemental Content

Support Center